Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)- (65-74) complement C5a

decapeptide agonist of human C5a; with substitutions in the C-terminal sequence (65-74); structure in first source

Also Known As:

complement C5a, (65-74), Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)-; 65-Tyr-67-Phe-69-Pro-71-Pro-73-Ala-complement 5a (65-74); C5a (65-74), Y65,F67,P69,P71,Ala73; EP54; YSFKPMPLaR; complement 5a (65-74), Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)-; complement 5a (65-74), tyrosyl(65)-phenylalanyl(67)-prolyl(69,71)-alanyl(73)-; tyrosyl-seryl-phenylalanyl-lysyl-prolyl-methionyl-prolyl-leucyl-alanyl-arginine

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Immunoproteins: 43
      - Complement System Proteins: 33379
        Anaphylatoxins: 563
        Complement C5a: 190
        Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)- (65-74) complement C5a: 5
        Complement C5: 270
        Complement C5a: 190
        Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)- (65-74) complement C5a: 5
- Peptides: 82426
  - Peptide Fragments: 373
    - Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)- (65-74) complement C5a: 5

Experts

1.	Akhir, Fazrena Nadia Md: 1 article (01/2021)
2.	Fung, Jenny Nga Ting: 1 article (01/2021)
3.	Leong, Keith Weng Kit: 1 article (01/2021)
4.	Manthey, Helga D: 1 article (01/2021)
5.	McGirr, Crystal E: 1 article (01/2021)
6.	Mills, Paul C: 1 article (01/2021)
7.	Nabizadeh, Jamileh A: 1 article (01/2021)
8.	Noor, Mohd Hezmee Mohd: 1 article (01/2021)
9.	Rolfe, Barbara E: 1 article (01/2021)
10.	Shiels, Ian A: 1 article (01/2021)

Related Diseases

1.	Neutropenia 10/01/1999 - "Given i.v., YSFKD(NMeNle)PLaR had similar activity to YSFKPMPLaR on blood pressure but did not cause neutropenia. " 09/01/1999 - "3 The order of potency human C5a>Ac-YSFKPMPLaR was conserved in bioassays based on rabbits (relaxation of the isolated portal vein and pulmonary artery; acute in vivo neutropenia), but with a decreasing potency gap between the two compounds, a likely consequence of the resistance to peptidases of the analogue. "
2.	Neoplasms (Cancer) 01/08/2021 - "However, treatment of mice with a dual C3aR/C5aR1 agonist (YSFKPMPLaR) significantly slowed mammary tumor development and progression. " 08/11/2011 - "Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model." 08/11/2011 - "Results are discussed against the backdrop of the ability of EP54/EP67 to selectively target antigens to and activate C5a receptor-bearing antigen presenting cells and the prospects of using such vaccines therapeutically against lymphoma and other cancers."
3.	B-Cell Lymphoma (Lymphoma, B Cell) 08/11/2011 - "Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model." 08/11/2011 - "Vaccines to large B cell lymphoma were made by the covalent attachment of an epitope from the gp70 glycoprotein (SSWDFITV) to the N-termini of the conformationally biased, response-selective C5a agonists EP54 (YSFKPMPLaR) and EP67 (YSFKDMP(MeL)aR). "
4.	Lymphoma (Lymphomas) 08/11/2011 - "Syngeneic Balb/c mice were immunized with these EP54/EP67-containing vaccines and challenged with a lethal dose of the highly liver metastatic and gp70-expressing lymphoma cell line RAW117-H10 to evaluate the ability of these vaccines to induce protective immune outcomes. " 08/11/2011 - "Results are discussed against the backdrop of the ability of EP54/EP67 to selectively target antigens to and activate C5a receptor-bearing antigen presenting cells and the prospects of using such vaccines therapeutically against lymphoma and other cancers."
5.	Hepatitis B 05/15/2000 - "A conformationally biased decapeptide agonist of human C5a anaphylatoxin (YSFKPMPLaR) was used as a molecular adjuvant in stimulating an Ag-specific CTL response against murine P815S target cells expressing an Ld-restricted CTL epitope of the hepatitis B surface Ag (HBsAg). "

Related Drugs and Biologics

1.	Epitopes
2.	Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)- (65-74) complement C5a
3.	Anaphylatoxin C5a Receptor
4.	Vaccines
5.	Peptides (Polypeptides)
6.	Peptide Hydrolases (Proteases)
7.	Hepatitis B Surface Antigens (HBsAg)
8.	Glycoproteins (Glycoprotein)
9.	Antigens
10.	Anaphylatoxins